Akt1

Overview

Akt1, also known as protein kinase B alpha, is a serine/threonine kinase that functions as a central node in the PI3K/AKT signaling network. It integrates upstream cues from growth factors, cytokines, metabolic signals, and stress responses to regulate cell survival, proliferation, metabolism, migration, autophagy, and apoptosis. In biomedical research, Akt1 is frequently studied alongside PTEN, mTOR, ERK, EGFR, SRC, GSK3β, and cGAS-STING-related signaling because changes in its phosphorylation state often reflect pathway activation or suppression.

As a target, Akt1 is especially prominent in cancer, metabolic disease, neuroinflammation, fibrosis, and tissue repair studies. Recent work has used Akt1 as a mechanistic readout for drug response, pathway crosstalk, and resistance biology, including contexts involving PD-L1 expression, FLT3 signaling, VEGF-associated neurobiology, and PI3K/AKT/mTOR-driven phenotypes. The studies summarized below largely focus on Akt1 phosphorylation or pathway modulation rather than direct structural characterization of the protein.

Focus of Latest Publications

Recent publications have examined Akt1 across diverse disease contexts, particularly in cancer pathology where the kinase serves as both a driver of malignancy and a therapeutic target. In hepatocellular carcinoma, CNOT9-mediated oncogenic signaling operates through the PTEN/AKT pathway, with studies demonstrating that CNOT9 knockdown reduces cell proliferation by inhibiting Akt activation. Similarly, in lung adenocarcinoma, CAMK2D isoform 15 promotes gefitinib resistance via Akt phosphorylation, suggesting Akt1 as a mechanism of acquired resistance. In gastric cancer, lenvatinib combined with PD-1 blockade suppresses immunosuppressive macrophages through inhibition of PDGFR/FGFR-dependent Akt signaling. Metastatic castration-resistant prostate cancer demonstrates Akt1 elevation in response to AKT monotherapy through c-MYC-driven resistance, prompting development of dual BRD4/AKT1 inhibitors that achieve substantial tumor growth inhibition.

Akt1 regulation has emerged as critical in metabolic disorders affecting adipose tissue and glucose homeostasis. Encapsulated luteolin promoted insulin sensitivity in white adipocytes through upregulation of insulin sensitivity-related genes and increased p-Akt protein levels, directly linking Akt1 phosphorylation to restored glucose metabolism. In obesity models, Pueraria lobata polysaccharides activated hepatic FGF21 signaling through Akt and ERK pathways, improving glucose tolerance and insulin sensitivity while modulating gut microbiota-mediated metabolic homeostasis. At the blood-brain barrier in Alzheimer's disease, butyrate reduces intraendothelial amyloid-beta accumulation through activation of insulin signaling, particularly Akt and ERK phosphorylation, which restores expression of the efflux transporter P-glycoprotein and the tight junction protein claudin-5.

Akt1 has emerged as a convergence point in neuroprotective and neuroregenerative responses. Spinal cord injury recovery was enhanced by platelet-rich plasma-primed bone marrow mesenchymal stem cell-derived exosomes operating through the miR-29a-3p/PTEN/PI3K/Akt/mTOR axis, inhibiting neuronal apoptosis and autophagy while promoting nerve regeneration. In depression, electroacupuncture ameliorated depressive-like behaviors by upregulating VEGF expression and promoting Akt1 phosphorylation, enhancing autophagy and reducing hippocampal neuroinflammation. In ischemic stroke, network pharmacology identified Akt1 among key molecular targets underlying neuroprotection through preserved blood-brain barrier integrity and angiogenesis.

Therapeutic strategies targeting Akt1 span kinase inhibition, pathway modulation, and indirect regulation through small-molecule and biologically-derived agents. Network pharmacology approaches have positioned Akt1 as a central hub in multimodal disease networks—in cancer immunity where it intersects with PD-L1 expression, in metabolic dysfunction where it couples with FGF21 and insulin signaling, and in neuroinflammation where it links autophagy with cytokine suppression. Notably, some kinase inhibitors such as masitinib paradoxically promote Akt1 phosphorylation through off-target mechanisms involving lysosomal sequestration, suggesting that subcellular drug distribution and indirect pathway activation complicate simple kinase inhibition strategies. These findings underscore Akt1 as a regulatory node integrating oncologic, metabolic, and neurological disease responses.

Key Publications

• NEWJul CNOT9 affects hepatocellular carcinoma proliferation and cell cycle through the PTEN/AKT/p53 signaling pathway. (Human cell, 2026, PMID 42384246): "CNOT9 knockdown activates PTEN to inhibit the AKT pathway and suppresses the expression of cell cycle-related proteins p53, p21, CCNE1 and CDK2."
• NEWJul A network pharmacology-based approach and molecular docking study to explore the therapeutic potential of a nutraceutical formula (Vernolac) in the treatment of cancer. (PloS one, 2026, PMID 42384725): "Protein-protein interaction analysis using STRING and Cytoscape revealed fourteen key hub nodes, including AKT1, BCL2, CASP3, CTNNB1, EGFR, ESR1, GAPDH, HSP90AA1, HSP90AB1, IL6, JUN, SRC, STAT3, and TNF."
• NEWJun Biomedical publication details. (PubMed Database, 2026, PMID 42283235)
• May Platelet-rich plasma-primed bone marrow mesenchymal stem cell-derived exosomes inhibit neuronal apoptosis and autophagy, and promote nerve regeneration via the miR-29a-3p/PTEN/PI3K/Akt/mTOR axis after spinal cord injury. (Journal of molecular histology, 2026, PMID 42165939): "Rescue experiments confirmed that the miR-29a-3p/PTEN/PI3K/Akt/mTOR axis may mediate the regulatory effects of PRP-BMSCs-EXO on neuronal apoptosis, autophagy, and nerve regeneration in SCI."
• Jun Biomedical publication details. (PubMed Database, 2026, PMID 42166642)
• May PRXL2B facilitates the progression of hepatocellular carcinoma and the therapeutic efficacy of oncolytic adenovirus H101 through the PI3K/AKT/PD-L1 axis. (Bioscience trends, 2026, PMID 42161529): "Mechanistically, PRXL2B silencing reduced AKT phosphorylation and PD-L1 expression."
• May CAMK2D isoform 15 facilitates gefitinib resistance via AKT phosphorylation in lung adenocarcinoma. (Cancer biology & medicine, 2026, PMID 42152470): "CAMK2D isoform 15 facilitates gefitinib resistance via AKT phosphorylation in lung adenocarcinoma."
• May Electroacupuncture Ameliorates Depressive-Like Behaviors by Enhancing Autophagy to Attenuate Hippocampal Neuroinflammation via the VEGF/AKT1/ERK Pathway in CUMS Rats. (Neurochemical research, 2026, PMID 42149321): "AKT1 was identified as a key gene linking autophagy and inflammation."
• May A venetoclax-cytarabine-based induction regimen incorporating a translation inhibitor for adult patients with de novo acute myeloid leukemia. (Cancer, 2026, PMID 42118656): "Translation inhibitors have been shown to accelerate acute myeloid leukemia (AML) cell apoptosis and regulate Akt activity and the Bcl-2 family, suggesting their potential benefit when combined with venetoclax and cytarabine in de novo AML patients."
• May Paeonol alleviates intrauterine adhesion by suppressing endometrial stromal cell activation via AKT1, based on network pharmacology. (Reproduction, fertility, and development, 2026, PMID 42062178): "Paeonol alleviates intrauterine adhesion by suppressing endometrial stromal cell activation via AKT1, based on network pharmacology."